|
IBRX | Immunitybio, Inc. |
|
|
IBRX | Immunitybio, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ -0.12 |
| Leverage | 200.85% |
| Market Cap | $ 4.4B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -348.2m |
| Margin | -426.17% |
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.